Specialty medicines

A category-defying portfolio

At Teva, we are a category-defying company. From in-house innovation to strategic partnerships, we are persistently discovering, developing and delivering both generic and innovative medicines.  

We are rethinking the way this creates value for patients – from re-evaluating our generics and innovative medicines portfolio, to pursuing new disease targets, novel treatments and biosimilars, while investing in our late-stage pipeline.  

Our legacy in high-quality generics enables us to leverage our capabilities to bring forward complex generics and biosimilars at scale to help create more value for patients and healthcare systems.  

We are focusing on complex drug design and leading-edge manufacturing to increase efficiency and bringing the most value to patients and healthcare systems, while creating more space for innovative research.  

This focus enables us to drive patient impact and business growth. We produce best-in-class innovations, broaden our reach across immunology and neuroscience, and hone our generics leadership to deliver complex generics and biosimilars that serve unmet patient needs and drive business growth.

Exploring the potential of biopharmaceuticals

We are investing in both original biologic medicines and in biosimilars to help patients around the world. Biopharmaceuticals are complex medicines made from living cells or organisms. They advance more treatment options for patients, some of whom suffer from untreated or undertreated conditions. They have the potential to deliver precise and personalised treatment.